A股异动 | 华海药业(600521.SH)涨逾5% 前三季度净利预增60%-70%
格隆汇9月30日丨昨日见逾3个月新低后,华海药业(600521.SH)今天反弹逾5%,报33.53元,总市值488亿元。华海药业昨日披露2020年三季度业绩预增公告,经财务部门初步测算,公司2020年1-9月实现归属于上市公司股东的净利润预计在8.2亿元至8.7亿元之间,与上年同期(法定披露数据)相比增长约60%到70%。公司2020年1-9月归属于上市公司股东的扣除非经常性损益的净利润预计在7.45亿元至8.2亿元之间,与上年同期(法定披露数据)相比增长约100%到120%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.